Background Weight regain after weight loss is a major problem in the treatment of persons
with obesity. Methods In a randomized, head-to-head, placebo-controlled trial, we enrolled …

Weight regain after weight loss remains a major challenge in obesity treatment and may
involve alteration of eating and sedentary behavior after weight loss. In this randomized …

Objective: Liraglutide, a once-daily human glucagon-like peptide-1 analog, induced
clinically meaningful weight loss in a phase 2 study in obese individuals without diabetes …

Importance Weight loss of 5% to 10% can improve type 2 diabetes and related
comorbidities. Few safe, effective weight-management drugs are currently available …

Background Obesity is a chronic disease with serious health consequences, but weight loss
is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like …

Objective Real‐world clinical effectiveness of liraglutide 3.0 mg, in combination with diet and
exercise, was investigated 4 and 6 months post initiation. Changes in absolute and percent …

Objective: Having demonstrated short-term weight loss with liraglutide in this group of obese
adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for …

Objective To identify an early response criterion for predicting≥ 5% weight loss with
liraglutide 3.0 mg at week 56 and to compare efficacy outcomes in early responders (ERs) …

Objective The Centers for Medicare and Medicaid Services (CMS) covers intensive
behavioral therapy (IBT) for obesity. The efficacy, however, of the specific approach has …

Aim We investigated the relationship between weight change and related factors in subjects
with type 2 diabetes mellitus (T2DM) treated with liraglutide versus comparator diabetes …